[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603686":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":115,"collaborators":11,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":11,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Autolus Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Obecabtagene autoleucel (obe-cel)","EXPERIMENTAL",null,[13],"Biological: Obecabtagene autoleucel (obe-cel)",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Obecabtagene autoleucel (obe-cel) given as a single infusion.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Autolus Ltd","CONTACT","+44 (0)203 911 4385","clinicaltrials@autolus.com",[26,44,55,67,80,91,104],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Stanford University","NOT_YET_RECRUITING","Redwood City","California","94063","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-122.23635,37.48522,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":11,"phoneExt":11,"email":11},"Jeffrey Dunn","PRINCIPAL_INVESTIGATOR",{"facility":45,"status":46,"city":47,"state":11,"zip":11,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":11},"Hospital Universitario Vall d'Hebron - PPDS","ACTIVE_NOT_RECRUITING","Barcelona","Spain","ES",{"type":35,"coordinates":51},[52,53],2.15899,41.38879,{"lat":53,"lon":52},{"facility":56,"status":57,"city":58,"state":11,"zip":11,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hospital Universitari i Politecnic La Fe de Valencia","RECRUITING","Valencia",{"type":35,"coordinates":60},[61,62],-0.37966,39.47391,{"lat":62,"lon":61},[65],{"name":66,"role":43,"phone":11,"phoneExt":11,"email":11},"Francisco P Miralles",{"facility":68,"status":57,"city":69,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Addenbrooke's Hospital","Cambridge","United Kingdom","UK",{"type":35,"coordinates":73},[74,75],0.11667,52.2,{"lat":75,"lon":74},[78],{"name":79,"role":43,"phone":11,"phoneExt":11,"email":11},"Nick Cunniffe",{"facility":81,"status":57,"city":82,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Western General Hospital Edinburgh - PPDSE Edinburgh","Edinburgh",{"type":35,"coordinates":84},[85,86],-3.19648,55.95206,{"lat":86,"lon":85},[89],{"name":90,"role":43,"phone":11,"phoneExt":11,"email":11},"Victoria Campbell",{"facility":92,"status":57,"city":93,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"The National Hospital for Neurology & Neurosurgery","London",{"type":35,"coordinates":95},[96,97],-0.12574,51.50853,{"lat":97,"lon":96},[100,102],{"name":11,"role":22,"phone":11,"phoneExt":11,"email":101},"uclh.car-ttrials@nhs.net",{"name":103,"role":43,"phone":11,"phoneExt":11,"email":11},"Wallace Brownlee",{"facility":105,"status":57,"city":106,"state":11,"zip":11,"country":70,"countryCode":71,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Royal Hallamshire Hospital","Sheffield",{"type":35,"coordinates":108},[109,110],-1.4659,53.38297,{"lat":110,"lon":109},[113],{"name":114,"role":43,"phone":11,"phoneExt":11,"email":11},"Basil Sharrack",{"type":116,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603686","phase-1-obe-cel-in-refractory-progressive-forms-of-multiple-sclerosis-100603686",false,"NCT07139743","Obe-cel in Refractory Progressive Forms of Multiple Sclerosis","A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis","BOBCAT","Inclusion Criteria:\n\n* Willing and able to give written informed consent for participation in the study.\n* Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.\n* Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding.\n* Current diagnosis of PMS.\n* Must have been treated previously with 2 disease-modifying therapies.\n\nExclusion Criteria:\n\n* Any medications prohibited by the protocol.\n* Highly active multiple sclerosis.\n* Diagnosis of another autoimmune central nervous system condition.\n* Active or uncontrolled fungal, bacterial, viral infection.\n* History of malignant neoplasms unless disease-free for at least 24 months.\n* History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.","ALL","18 Years","60 Years",{"count":129,"type":130},18,"ESTIMATED","INTERVENTIONAL",[133],"PHASE1","The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies.\n\nUpon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.\n\nParticipants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.",[136],"Progressive Multiple Sclerosis",[138,139,140,141,142],"Multiple sclerosis","Refractory multiple sclerosis","Progressive multiple sclerosis","Obecabtagene autoleucel","Obe-cel","2026-03-20",{"date":145,"type":146},"2026-03-23","ACTUAL",{"date":148,"type":146},"2025-08-04",{"date":150,"type":130},"2029-08-15",{"name":5,"class":6},7]